Osteoprotegerin (OPG), also known as Tumor necrosis factor receptor superfamily member 11B, is a member of the tumor necrosis factor receptor superfamily that lacks any apparent cell association motifs and exists as a soluble secreted protein. OPG acts as a decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. OPG may act as decoy receptor for TRAIL and protect against apoptosis. Several studies have shown that serum markers of bone turnover may be able to determine the time-to-tumor progression, metastatic potential, and overall survival in cancer patients.
Swiss-Prot Accession Number: O00300
Publications Biomarker panels associated with progression of renal disease in type 1 diabetes.
(2019) Colombo M, Valo E, McGurnaghan SJ, Sandholm N, Blackbourn LAK, Dalton RN, Dunger D, Groop PH, McKeigue PM, Forsblom C, Colhoun HM Diabetologia
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment
(2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Effect of Low-Magnitude, High-Frequency Mechanical Stimulation on Bmd among Young Childhood Cancer Survivors: A Randomized Clinical Trial
(2016) Mogil RJ, Kaste SC, Ferry Jr RJ, Hudson MM, Mulrooney DA, Howell CR, Partin RE, Srivastava DK, Robison LL, Ness KK JAMA Oncology
Variation in Serum Biomarkers with Sex and Female Hormonal Status: Implications for Clinical Tests
(2016) Ramsey JM, Cooper JD, Penninx BWJH, Bahn S Scientific Reports
Identifying Novel Biomarkers for Cardiovascular Events or Death in People with Dysglycemia
(2015) Gerstein HC, ParÃ© G, Mcqueen MJ, Haenel H, Lee SF, Pogue J, Maggioni AP, Yusuf S, Hess S Circulation